Clinical trials: Non-hematologic Malignancies
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
This research study is being conducted to evaluate an experimental drug called huCART19-IL18-CD428z cells in patients living with HIV who have been diagnosed with Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)…
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation
- Trial name
- NCT07891468
- Testing
- huCART19-IL18-CD428z cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Pennsylvania
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
RATIONALE: Questionnaires that measure coping may improve the ability to plan supportive care for patients undergoing donor bone marrow transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281814
- Testing
- psychosocial assessment and care
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- The Cleveland Clinic
Solid Tumors
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
- Trial name
- NCT00688116
- Testing
- STA 9090 (ganetespib)
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Synta Pharmaceuticals Corp.
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer.
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
- Trial name
- NCT07162181
- Testing
- Pirtobrutinib
- Where
- 6 sites in China
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood SCT…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy
- Trial name
- FLAT-Auto (NCT03961919)
- Testing
- Fludarabine, ARA-C, Treosulfan
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Ciceri Fabio
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
This pilot study examines the safety and efficacy of anti-CD19 CAR T cells manufactured on-site in children and young adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission
- Trial name
- NCT05779930
- Testing
- CD19 specific Chimeric Antigen Receptor T Cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nationwide Children's Hospital
Fever, Sweats, and Hot Flashes, Infection
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00020865
- Testing
- cefepime hydrochloride, levofloxacin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia, Non Hodgkin Lymphoma
Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families
This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.
- Trial name
- NCT05425992
- Testing
- Interview
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Osteonecrosis
Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis
Although uncommon in the general pediatric population, osteonecrosis (ON) is prevalent in children and adolescents with cancer, particularly among those that have had chronic exposure to glucocorticoids and among those having…
- Trial name
- NCT02458937
- Testing
- Functional Mobility Assessment, GAITRite® System, Range of Motion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- St. Jude Children's Research Hospital
T-cell Lymphoma
Study of Tazemetostat in Lymphoid Malignancies
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test…
- Trial name
- NCT05983965
- Testing
- Tazemetostat
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham
Cancer
Influenza Vaccination in Cancer Patients
The purpose of this study is to determine the timing of influenza vaccination to induce higher antibody response in adult patients with non-hematologic malignancies receiving scheduled cytotoxic chemotherapy.
- Trial name
- NCT02213432
- Testing
- Different timing of influenza vaccination
- Where
- South Korea
- Volunteers
- 97 people
- Sponsor
- Seoul National University Hospital
Marfan Syndrome, Turner Syndrome
National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions
The National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC) was initiated in 2006 by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of…
- Conditions
- Marfan Syndrome, Turner Syndrome, Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome
- Trial name
- GenTAC (NCT01322165)
- Where
- 7 sites in United States
- Volunteers
- 3,706 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00007865
- Testing
- rituximab, carboplatin, etoposide
- Where
- United States
- Sponsor
- University of Nebraska
Lymphoma, Small Intestine Cancer
S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049400
- Testing
- BMS-247550
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- SWOG Cancer Research Network
Cancer
Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg
Hospitalization at home is booming. It is designed to meet the demands of patients and their families to continue care at home. It partially solves the problem of the lack of places in the "long-term care" structures and allows…
- Trial name
- NCT03217864
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.